

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No.: EL676224336US

Date of Deposit: March ²⁹, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Tamara Venegas

Tamara Venegas

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Thomas INNERARITY and Jan BOREN

Serial No.: To Be Assigned

Filing Date: Herewith

For: METHODS AND TOOLS FOR
IDENTIFYING COMPOUNDS WHICH
MODULATE ATHEROSCLEROSIS BY
IMPACTING LDL-PROTEOGLYCAN
BINDING

Examiner: To Be Assigned

Group Art Unit: To Be Assigned

PRELIMINARY AMENDMENT

Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

The above-referenced application is a divisional under 37 C.F.R. § 1.53(b) of Application No. 09/265,222. Prior to examination on the merits, applicants respectfully request that the following amendment be entered and considered.

In the Specification

On page 1, under the title, please insert the following new paragraph:

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional application of application Serial. No. 09/265,222, filed March 5, 1999, which claims priority under 35 USC § 119(e) to U.S. Provisional Application Serial No. 60/077,618, filed March 10, 1998, the entire contents of which are incorporated herein by reference.

In the claims

Please cancel claims 1-13, 15-17, and 21-28 without prejudice or disclaimer.

Please amend claims 14 and 19-20 as follows:

14. (Once Amended) An apo-B100 protein comprising a proteoglycan receptor⁺ mutation in Site B.
19. (Once Amended) A polypeptide comprising the amino acid sequence of Site B in the apo-B100 protein according to claim 14, wherein said Site B is flanked on at least one side by a contiguous sequence of at least 10 amino acids which is directly adjacent to Site B in the wild-type human apo-B100 sequence.
20. (Once Amended) An LDL particle comprising an apo-B100 protein according to claim 14.

REMARKS

Following entry of this preliminary amendment, claims 14 and 18-20 will be pending in the present application. Claim 14 has been amended to correct a typographical error, and claims 19 and 20 have been amended to correct dependencies. No new matter has been added.

Attached hereto is a marked up version of the changes made to the claims and specification by the current amendment with additions underlined and deletions bracketed. The attached page is captioned "**VERSION WITH MARKINGS TO SHOW CHANGES MADE**"

In the unlikely event that the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and

authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing docket no. 220002059710. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: March 29, 2001

By: Cara Coburn
Cara Coburn
Registration No. 46,631

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-4218
Facsimile: (650) 494-0792

VERSION WITH MARKINGS TO SHOW CHANGES MADE

U.S. Serial No. (to be assigned)
Attorney Docket No. 220002059710

In the specification

At page 1, under the title, a new paragraph has been added.

In the claims

14. (Once Amended) An apo-B100 protein comprising a proteoglycan receptor⁺ mutation in Site B.

19. (Once Amended) A polypeptide comprising the amino acid sequence of Site B in the apo-B100 protein according to claim 14 [any one of claims 14 to 18], wherein said Site B is flanked on at least one side by a contiguous sequence of at least 10 amino acids which is directly adjacent to Site B in the wild-type human apo-B100 sequence.

20. (Once Amended) An LDL particle comprising an apo-B100 protein according to claim 14 [any one of claims 14 to 18].